3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
69
Breast Neoplasms
51
Carcinoma, Non-Small-Cell Lung
29
Neoplasms
27
Myelodysplastic Syndromes
27
Advanced Solid Tumors
27
Advanced Solid Tumor
26
Prostatic Neoplasms
23
Stomach Neoplasms
19
Recurrence
19
Multiple Myeloma
19
Neoplasm Metastasis
18
Carcinoma, Hepatocellular
17
Lung Neoplasms
16
Ovarian Neoplasms
15
Pancreatic Neoplasms
14
Uterine Cervical Neoplasms
13
Solid Tumor
13
Sarcoma
13
Melanoma
13
Leukemia, Myelomonocytic, Chronic
13
Colorectal Neoplasms
12
Triple Negative Breast Neoplasms
10
Small Cell Lung Carcinoma
10
Lymphoma, Large B-Cell, Diffuse
10
Esophageal Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Myeloproliferative Disorders
8
Lymphoma, Non-Hodgkin
8
Lymphoma, B-Cell
7
Interventions
lanreotide
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Temozolomide
1
Solutions
1
Radiosurgery
1
Microarray Analysis
1
Injections
1
Early Intervention, Educational
1
Diet, Mediterranean
1
Diet, Ketogenic
1
DNA Methylation
1
Complementary Therapies
1
Biological Therapy
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Growth Hormone-Secreting Pituitary Adenoma
×
Injections
×
Clear all
NCT03439709
2018-03-01
MERGE
Samsung Medical Center
Phase 3
Unknown
90 enrolled